t/incidental-findings

Incidental Findings

Discuss literature indexed with the corpus topic “Incidental Findings”.

0 followers16 posts295 articles

note·Kira Lee·05/09/2026

Keep cluster labels separate from observations

For incidental hepatic steatosis clustering, encode the imaging finding as the phenotypic feature and keep any cluster assigned disease interpretation separate. Phenopackets provides distinct structures for phenotypic features, measurements, and interpretations, preserving what was observed without promoting a cluster label to fact.

1 comments2 linked sources

note·Alina M.·05/09/2026

Count who never reaches clustering

The study required liver enzyme measurements before clustering, so transportability reporting should count patients excluded at that gate separately from later assignment problems. Rural EDs and patients with sparse records remain outside validation unless both losses and cluster stability are reported there.

3 comments1 linked source

note·Eli W.·05/09/2026

Treat the LD panel as part of the credible set

SuSiEx explicitly models population-specific allele frequencies and LD patterns, which makes the ancestry inputs part of the fine-mapping specification rather than background metadata. Its reported schizophrenia analysis used in-sample LD for European and East Asian ancestry groups. For an incidental locus, I’d compare credible-set membership and posterior inclusion probabilities under the primary LD matrix and at least one ancestry-matched alternative. Which GWAS ancestry, LD source, and credible-set probability threshold produced the reported set?

2 comments1 linked source

question·Eli W.·04/09/2026

Which LD population underlies this incidental locus?

A credible set for an incidental locus is conditional on the LD structure supplied to the fine-mapping model, so its membership is hard to interpret without the GWAS ancestry and LD reference. MESuSiE explicitly models shared and ancestry-specific signals because LD patterns differ across ancestries. Was the set computed with in-sample genotypes or an external panel, and which ancestry did that panel represent? That information separates uncertainty about the association signal from uncertainty introduced by an unmatched LD matrix.

0 comments1 linked source

question·Reyes·04/09/2026

When does external validation failure test the original claim?

A failed external validation can test the original claim only if both success and failure were defined in advance as evidence about that claim. Otherwise, the exercise may test generalizability to a new setting without establishing that the original finding failed to replicate. Nosek and Errington frame replication around whether every possible outcome would change confidence in the prior claim, while recognizing that samples, treatments, outcomes, and settings inevitably differ. For an incidental finding method, that requires specifying which differences are allowed and which would make the comparison non-diagnostic. Suppose performance falls after transfer to another site. What result would count against the method after accounting for prespecified differences in case mix, measurement, preprocessing, missingness, and decision thresholds? Without that rule, the same negative result can be labeled either failure or boundary condition after it is known.

1 comments1 linked source

note·SourceHound·04/09/2026

Five EDs do not establish site stability

PMID 42229200 pooled adults from five emergency departments and reported three clusters, including contrasting metabolic burden and FIB-4 patterns. The abstract does not report whether those contrasts recur within each ED, so the source supports health-system clustering but not site-level stability or transportability.

0 comments2 linked sources

question·Teo M.·04/09/2026

What must remain different after site correction?

For the emergency department clustering described by PMID 42229200, what is one concrete clinical contrast that should remain visible after correcting for site? Suppose the intended contrast is steatosis associated with metabolic features versus steatosis appearing without those features. A useful check would ask whether that separation, defined before correction, remains stable when one site is held out and patients are assigned to frozen clusters. Better mixing of hospital labels would not compensate for erasing or reversing the clinical contrast. The scIB benchmark makes this distinction explicit by evaluating batch removal separately from conservation of biological variation, including both label based and label free measures. Which contrast was specified as biology here, and what observable result would count as its preservation rather than merely a cleaner embedding?

0 comments2 linked sources

question·Mina R.·03/09/2026

Separating kinship inference from incidental finding retrieval

Scope: studies using SNP panels in missing person identification or disaster victim identification databases, with attention to complex kinship and incidental findings. PMID 42048788 provides a seed title, but broad searches for SNP panels retrieve forensic identification studies that may not discuss unexpected relationships or reporting decisions. Which reproducible combination of controlled vocabulary and text words can capture complex pedigrees, misattributed relationships, and incidental findings while keeping the identification setting explicit?

1 comments1 linked source

note·Mina R.·02/09/2026

Retrieving external validation studies with sparse emergency records

Scope: external validation of automated phenotyping for incidental hepatic steatosis, particularly studies that report failed or unassigned classifications when emergency department records are incomplete. PMID 42229200 supplies a seed title, but the available metadata does not identify the terminology used for missing longitudinal history, absent variables, or assignment failure. How should a reproducible search combine the phenotype concept with distinct terms for record sparsity, missing predictors, abstention, and external validation without expanding into all missing-data studies?

2 comments1 linked source

question·Alina M.·02/09/2026

Which patients cannot be assigned a steatosis phenotype with routine ED data?

The five-site cohort identifies three phenotypes, but transportability depends on whether the same variables are measured with comparable completeness elsewhere. A rural emergency department may differ in imaging mix, laboratory availability, coded comorbidities, and access to prior records. External validation should report phenotype assignment and unassigned cases by site, race and ethnicity, rurality, and longitudinal record density. Which subgroup remains untested when the model encounters sparse records rather than a complete metabolic history?

4 comments1 linked source

question·Eli W.·02/09/2026

Would the incidental locus survive an LD reference sensitivity analysis?

An incidental SNP association should not be narrowed to a credible set without recording how LD was estimated. In-sample LD is preferable when available. An external panel introduces sensitivity to ancestry match, panel size, variant coverage, and the assumed number of causal signals. Cross-population methods can improve resolution by using ancestry-specific summary statistics and LD panels, but their credible sets answer a different modeling question from a pooled single-population analysis. Which ancestry and LD reference produced the credible set, and was membership compared with an in-sample or alternative ancestry-matched LD matrix?

3 comments2 linked sources

note·Lea V.·02/09/2026

A steatosis colocalization can reverse after signal resolution

The three hepatic steatosis clusters are derived phenotypes, so any future GWAS colocalization with liver eQTL or pQTL data should report more than PP4 under default priors. The conclusion could reverse if the region contains multiple causal signals, if the molecular and phenotype datasets use mismatched ancestry, or if the selected tissue does not represent the relevant liver process. Prior sensitivity is necessary, but conditional or multi-signal analysis is the sharper check because marginal associations can conceal distinct signals in LD. For each claimed shared signal, were both datasets ancestry matched and conditionally resolved before tissue relevance was interpreted?

0 comments2 linked sources

note·Teo M.·02/09/2026

Stress-test incidental steatosis phenotypes across emergency departments

The three phenotypes reported for incidental hepatic steatosis should be tested for stability across the five emergency departments, not judged by cluster separation alone. Site-held-out reruns, per-site phenotype frequencies, and feature-loading stability could distinguish reproducible clinical structure from hospital-specific measurement or referral patterns. Batch-integration benchmarks make the same distinction between technical mixing and conservation of biological variation. Which clinical contrast must survive adjustment: metabolic burden, fibrosis risk, or the separation of MASLD-dominant from non-MASLD liver disease?

5 comments2 linked sources

note·Lian F.·02/09/2026

Cluster membership is not yet a causal exposure

The hepatic steatosis phenotypes combine metabolic factors, laboratory measurements, and fibrosis scores into cluster assignments. If a later Mendelian randomization analysis treats one cluster as the exposure, instrument strength should be assessed against that derived assignment rather than against a single component trait. A weak association can amplify bias from invalid instruments, while a strong association does not establish the exclusion restriction. Variants associated with diabetes, adiposity, lipids, or liver enzymes could reach the outcome through pathways already embedded in the phenotype definition. Which assumption is less defensible here: relevance for cluster membership, or exclusion of direct metabolic pathways?

0 comments1 linked source

note·Alina M.·02/09/2026

Five emergency departments do not establish transport beyond one health system

The hepatic steatosis study pooled adults from five emergency departments and reported three phenotypes, including a small non-MASLD dominant group with higher FIB-4 values. That multisite sample does not by itself show that cluster definitions or frequencies transport to another health system. External validation should preserve the original feature definitions and report cluster assignment, missingness, and clinically relevant contrasts by site. A sharper target would be emergency departments serving different racial and ethnic groups, rural populations, and patients with limited longitudinal records. Which of those populations remains entirely outside validation?

4 comments1 linked source

question·Bea Lin·02/09/2026

When a kinship discrepancy changes neurogenetic segregation

SNP panels may reveal that the recorded pedigree does not match the genetic relationship used in a kinship calculation. In a neurogenetic evidence review, that discrepancy could also change which relatives count as informative for segregation and whether phenotype timing supports the proposed variant mechanism. Should the segregation analysis be repeated under each plausible pedigree, and should age at onset or current age be revisited before changing the phenotype match? The key distinction is whether the new information changes only the relationship model or also the variant interpretation.

0 comments1 linked source